Silence Therapeutics Prices Upsized $175M Offering at $13.50/ADS, an 8.3% Discount
SLN has more than doubled off its 52-week low of $4.19 on elevated volume (6.6× avg).
Summary
Silence Therapeutics priced its upsized $175 million underwritten offering at $13.50 per ADS, an 8.3% discount to the prior close, raising $164 million net to fund divesiran development.
Key Events · Financing and Capital Events · SLN
-
Offering Priced at $13.50/ADS
12,962,963 ADSs priced at $13.50 each, an 8.3% discount to the August 11 close of $14.72, for gross proceeds of $175 million.
-
Net Proceeds of $164 Million
After $10.5 million in underwriting commissions (6%) and $0.46 million in expenses, net proceeds are $164.0 million, or $188.7 million if the 1,944,444 ADS over-allotment option is fully exercised.
-
Dilution of ~27%
The offering adds 12.96 million ADSs to the 47.25 million outstanding, increasing share count by approximately 27%. New investors face immediate dilution of $10.32 per ADS based on net tangible book value.
-
Use of Proceeds
Proceeds will fund continued clinical development of divesiran and other product candidates, plus working capital and general corporate purposes. Cash runway extends into 2030.
Analysis · SLN · Life Sciences
The upsized underwritten offering has been finalized, with 12.96 million ADSs priced at $13.50 each—an 8.3% discount to the prior close of $14.72. Gross proceeds reach $175 million, yielding $164 million net to fund clinical development of divesiran and general corporate purposes. This pricing arrives just two days after blockbuster Phase 2 data for divesiran in polycythemia vera, and the offering was upsized from $150 million to $175 million on strong demand. The discount is modest for a biotech follow-on, and the upsizing signals institutional confidence in the data. However, the offering is highly dilutive: it increases outstanding ADSs by approximately 27% (12.96 million new ADSs vs. 47.25 million outstanding), and new investors face immediate dilution of $10.32 per ADS based on net tangible book value. With these proceeds, the company's cash runway extends into 2030, removing near-term financing risk.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLN was trading at $13.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $695.5M. The 52-week trading range was $4.19 to $17.58. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.